 Biocept Inc NASDAQ:BIOC FRA:B003 revealed to investors that it has received more than 420,000 samples for coronavirus testing since launching the service in June 2020. The samples are processed using Biocepts RT-PCR-based technology at its CLIA-certified, CAP-accredited, high-complexity molecular laboratory in San Diego. 